Celyad Oncology S.A. (0QFK.L) LSE
Currency In EUR
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 7.27M |
| Enterprise Value | 5.56M |
| P/E Ratio | 2.65 |
| PEG Ratio | 0 |
| Price/Sales Ratio | 1,406.8 |
| Price/Book Ratio | 7.84 |
| Enterprise/Revenue | 1,393.09 |
| Enterprise/EBITDA | -2.08 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | December 31, 2025 |
Profitability
| Profit Margin | 470.71 |
| Operating Margin | -687.29 |
AD
Management Effectiveness
| Return On Assets | 1.42 |
| Return On Equity | 1.78 |
Income Statement
| Revenue | 21,000 |
| Revenue/Share | 0 |
| Gross Profit | 1.93M |
| EBITDA | -7.01M |
| Net Income | 830,000 |
| Diluted EPS | 0.02 |
Balance Sheet
| Total Cash | 1.71M |
| Total Cash/Share | 0 |
| Total Debt | 0 |
| Total Debt/Equity | 0.02 |
| Current Ratio | 0.94 |
| Book Value Per Share | 0.03 |
Price History
| 52-Week Change | -51.39 |
| 52-Week High | 1.23 |
| 52-Week Low | 0.18 |
| Moving Average 50 Days | 0.51 |
| Moving Average 200 Days | 0.6 |
Statistics
| Average Volume | 1,098 |
| Shares Outstanding | 27.62M |
| % Held by Institutions | N/A |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
AD
